Cited by 608Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchRadiopharmaceutical Chemistry and Applications

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

Xia, Chun‐Fang, Arteaga, Janna, Chen, Gang, Gangadharmath, Umesh, Gomez, Luis F., Kasi, Dhanalakshmi, Lam, Chung, Liang, Qianwa, Liu, Changhui, Mocharla, Vani P., Mu, Fanrong, Sinha, Anjana, Su, Helen, Szardenings, A. Katrin, Walsh, Joseph C., Wang, Eric, Yu, Chul, Zhang, Wei, Zhao, Tieming, Kolb, Hartmuth C.·2013·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2012.11.008

Open this paper in CoChat — free account

Abstract

OBJECTIVE: We wished to develop a highly selective positron emission tomography (PET) imaging agent targeting PHF-tau in human Alzheimer's disease (AD) brains. METHODS: To screen potential tau binders, human AD brain sections were used as a source of native paired helical filament (PHF)-tau and Aβ rather than synthetic tau aggregates or Aβ fibrils generated in vitro to measure the affinity and selectivity of [(18)F]T807 to tau and Aβ. Brain uptake and biodistribution of [(18)F]T807 in mice were also tested. RESULTS: In vitro autoradiography results show that [(18)F]T807 exhibits strong binding to PHF-tau-positive human brain sections. A dissociation constant (Kd) of [(18)F]T807 (14.6 nM) was measured using brain sections from the frontal lobe of AD patients. A comparison of autoradiography and double immunohistochemical staining of PHF-tau and Aβ on adjacent sections demonstrated that [(18)F]T807 binding colocalized with immunoreactive PHF-tau pathology, but did not highlight Aβ plaques. In vivo studies in mice demonstrated that [(18)F]T807 was able to cross the blood-brain barrier and washed out quickly. CONCLUSIONS: [(18)F]T807 demonstrates high affinity and selectivity to PHF-tau as well as favorable in vivo properties, making this a promising candidate as an imaging agent for AD.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2012.11.008

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Neurofibrillary lesions develop at specific high-risk sites, and follow a highly characteristic pattern with regard to affected cell types, cell layers, and brain regions, with only minor interindividual variations [30].”
Background
Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Neurodegenerative Tauopathies
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Alzheimer’s Dementia
Melnick, V. L., & Dubler, N. N. (1985) · Contemporary Issues in Biomedicine, Ethics, and Society · doi:10.1007/978-1-4612-5174-3 · Cited by 1,986
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611

Flagged first, then by citations

Show all 41 references

1 of the 41 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

10.1097/00019442-200411000-00004 · DOI
Zeng Z, 2012, Presented at the Alzheimer's Association International Conference

Sorted by citations

Items 201–300 of 608

A Difluoroboron β-Diketonate Probe Shows “Turn-on” Near-Infrared Fluorescence Specific for Tau Fibrils
Park, K., Kim, M. K., Seo, Y., Ha, T., Yoo, K., Hyeon, S. J., Hwang, Y. J., Lee, J.-H., Ryu, H., Choo, H., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00224 · Cited by 51
MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy
Whitwell, J. L., Tosakulwong, N., Schwarz, C. G., Botha, H., Senjem, M. L., Spychalla, A. J., Ahlskog, J. E., Knopman, D. S., Petersen, R. C., Jack, C. R., et al. (2018) · Movement Disorders · doi:10.1002/mds.27546 · Cited by 49
PET imaging of neural activity, β-amyloid, and tau in normal brain aging
Zhang, K., Mizuma, H., Zhang, X., Takahashi, K., Jin, C., Song, F., Gao, Y., Kanayama, Y., Wu, Y., Li, Y., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05230-5 · Cited by 49
The emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 52
Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech
Utianski, R. L., Whitwell, J. L., Schwarz, C. G., Senjem, M. L., Tosakulwong, N., Duffy, J. R., Clark, H. M., Machulda, M. M., Petersen, R. C., Jack, C. R., et al. (2018) · Cortex · doi:10.1016/j.cortex.2017.12.021 · Cited by 54
Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase.
Drake, L., Pham, J. M., Desmond, T., Mossine, A. V., Lee, S. J., Kilbourn, M., Koeppe, R., Brooks, A. F., & Scott, P. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00326 · Cited by 45
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease
Barba, L., Abu‐Rumeileh, S., Barthel, H., Massa, F., Foschi, M., Bellomo, G., Gaetani, L., Thal, D. R., Parnetti, L., & Otto, M. (2024) · Brain · doi:10.1093/brain/awae203 · Cited by 52
Positron emission tomography of tau in Iraq and Afghanistan Veterans with blast neurotrauma
Robinson, M. E., McKee, A. C., Salat, D. H., Rasmusson, A. M., Radigan, L. J., Catana, C., Milberg, W., & McGlinchey, R. E. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101651 · Cited by 47
Dementia spectrum disorders: lessons learnt from decades with PET research
Wilson, H., Pagano, G., & Politis, M. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01975-4 · Cited by 50
State-of-the-art imaging of neuromodulatory subcortical systems in aging and Alzheimer’s disease: Challenges and opportunities
Engels, N., Koops, E. A., Prokopiou, P. C., Egroo, M. V., Schneider, C., Riphagen, J. M., Singhal, T., & Jacobs, H. I. L. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104998 · Cited by 45
Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers
Koychev, I. G., Hofer, M., & FRIEDMAN, N. C. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230458 · Cited by 52
Deep learning-based amyloid PET positivity classification model in the Alzheimer’s disease continuum by using 2-[18F]FDG PET
Kim, S. H., Lee, P., Oh, K. T., Byun, M. S., Yi, D., Lee, J. H., Kim, Y. K., Ye, B. S., Yun, M., Lee, D. Y., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00798-3 · Cited by 45
Quantification of Tau Load Using [18F]AV1451 PET
Golla, S. S. V., Timmers, T., Ossenkoppele, R., Groot, C., Verfaillie, S. C. J., Scheltens, P., van der Flier, W. M., Schwarte, L. A., Mintun, M. A., Devous, M. D., et al. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1080-z · Cited by 44
Synthesis of Thiophene‐Based Optical Ligands That Selectively Detect Tau Pathology in Alzheimer's Disease
Shirani, H., Appelqvist, H., Bäck, M., Klingstedt, T., Cairns, N. J., & Nilsson, K. P. R. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201703846 · Cited by 45
Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
Leuzy, A., Cicognola, C., Chiotis, K., Saint‐Aubert, L., Lemoine, L., Andreasen, N., Zetterberg, H., Ye, K., Blennow, K., Höglund, K., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4242-6 · Cited by 48
In vivo measures of tau burden are associated with atrophy in early Braak stage medial temporal lobe regions in amyloid‐negative individuals
Das, S. R., Xie, L., Wisse, L. E. M., Vergnet, N., Ittyerah, R., Cui, S., Yushkevich, P. A., Wolk, D. A., & Initiative, A. D. N. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.05.009 · Cited by 47
What’s That (Blue) Spot on my MRI? Multimodal Neuroimaging of the Locus Coeruleus in Neurodegenerative Disease
Kelberman, M. A., Keilholz, S. D., & Weinshenker, D. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.583421 · Cited by 46
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
Wolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Hansson, O., Nordberg, A. K., Frisoni, G. B., Garibotto, V., & Ossenkoppele, R. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05118-w · Cited by 48
[18F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
Bevan Jones, W. R., Cope, T. E., Passamonti, L., Fryer, T. D., Hong, Y. T., Aigbirhio, F., Kril, J. J., Forrest, S. L., Allinson, K., Coles, J. P., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.366 · Cited by 44
Recent developments with tau-based drug discovery
Iqbal, K., Liu, F., & Gong, C. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1445084 · Cited by 46
Preoperative Phosphorylated Tau Concentration in the Cerebrospinal Fluid Can Predict Cognitive Function Three Years after Shunt Surgery in Patients with Idiopathic Normal Pressure Hydrocephalus
Nakajima, M., Miyajima, M., Ogino, I., Akiba, C., Kawamura, K., Kamohara, C., Fusegi, K., Harada, Y., Hara, T., Sugano, H., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180557 · Cited by 43
Structure–Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimer’s Disease Brains
Matsumura, K., Ono, M., Kitada, A., Watanabe, H., Yoshimura, M., Iikuni, S., Kimura, H., Okamoto, Y., Ihara, M., & Saji, H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00440 · Cited by 43
Identification of a major radiometabolite of [ 11 C]PBB3
Hashimoto, H., Kawamura, K., Takei, M., Igarashi, N., Fujishiro, T., Shiomi, S., Watanabe, R., Muto, M., Furutsuka, K., Ito, T., et al. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.08.006 · Cited by 44
The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function
Dowling, N. M., Johnson, S. C., Gleason, C. E., & Jagust, W. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.10.050 · Cited by 43
Neuroimaging assessment of early and late neurobiological sequelae of traumatic brain injury: implications for CTE
Sundman, M., Doraiswamy, P. M., & Morey, R. A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00334 · Cited by 46
Early Tau Burden Correlates with Higher Rate of Atrophy in Transentorhinal Cortex
Xie, L., Das, S. R., Wisse, L. E. M., Ittyerah, R., Yushkevich, P. A., Wolk, D. A., & Initiative, A. D. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170945 · Cited by 43
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
Wolters, E. E., Ossenkoppele, R., Verfaillie, S. C. J., Coomans, E. M., Timmers, T., Visser, D., Tuncel, H., Golla, S. S. V., Windhorst, A. D., Boellaard, R., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04758-2 · Cited by 45
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00653-x · Cited by 44
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes
Schönecker, S., Brendel, M., Palleis, C., Beyer, L., Höglinger, G. U., Schuh, E., Rauchmann, B., Sauerbeck, J., Rohrer, G., Sonnenfeld, S., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00249 · Cited by 44
[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series
Marquié, M., Agüero, C., Amaral, A. C. S., Villarejo‐Galende, A., Ramanan, P., Chong, M. S. T., Saez-Calveras, N., Bennett, R. E., Verwer, E. E., Kim, S. J. W., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0808-1 · Cited by 43
Evaluation of a visual interpretation method for tau‐PET with 18 F‐flortaucipir
Sonni, I., Lesman‐Segev, O. H., Baker, S. L., Iaccarino, L., Korman, D., Rabinovici, G. D., Jagust, W. J., Landau, S. M., Joie, R. L., & Initiative, A. D. N. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12133 · Cited by 45
Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer’s Disease
Rombouts, F. J. R., Andrés, J.-I., Ariza, M., Alonso, J. M., Austin, N. E., Bottelbergs, A., Chen, L., Chupakhin, V., Cleiren, E., Fierens, K., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01173 · Cited by 42
Self-citation
Data‐driven approaches for tau‐PET imaging biomarkers in Alzheimer's disease
Vogel, J. W., Mattsson, N., Iturria‐Medina, Y., Strandberg, O. T., Schöll, M., Dansereau, C. L., Villeneuve, S., van der Flier, W. M., Scheltens, P., Bellec, P., et al. (2018) · Human Brain Mapping · doi:10.1002/hbm.24401 · Cited by 44
Chalcones and Five-Membered Heterocyclic Isosteres Bind to Alpha Synuclein Fibrils in Vitro
Hsieh, C., Xu, K., Lee, I., Graham, T. J. A., Tu, Z., Dhavale, D. D., Kotzbauer, P. T., & Mach, R. H. (2018) · ACS Omega · doi:10.1021/acsomega.7b01897 · Cited by 41
Neuronal levels and sequence of tau modulate the power of brain rhythms
Das, M. M., Maeda, S., Hu, B., Yu, G.-Q., Guo, W., Lopez, I., Yu, X., Tai, C., Wang, X., & Mucke, L. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.020 · Cited by 42
First Human Use of a Radiopharmaceutical Prepared by Continuous-Flow Microfluidic Radiofluorination: Proof of Concept with the Tau Imaging Agent [ 18 F]T807
Liang, S. H., Yokell, D. L., Normandin, M. D., Rice, P. A., Jackson, R. N., Shoup, T. M., Brady, T. J., Fakhri, G. E., Collier, T. L., & Vasdev, N. (2014) · Molecular Imaging · doi:10.2310/7290.2014.00025 · Cited by 40
Characterization of 18F-PM-PBB3 (18F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy
Weng, C.-C., Hsiao, I., Yang, Q.-F., Yao, C.-H., Tai, C., Wu, M., Yen, T., Jang, M., & Lin, K. (2020) · Molecules · doi:10.3390/molecules25071750 · Cited by 40
Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases
Schwarz, C. G. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01030-9 · Cited by 40
Recent imaging advances in neurology
Rocchi, L., Niccolini, F., & Politis, M. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7711-x · Cited by 40
Advanced Neuroimaging of Mild Traumatic Brain Injury
Koerte, I. K., Hufschmidt, J., Muehlmann, M., Lin, A. P., & Shenton, M. E. (2016) · Europe PMC (PubMed Central) · Cited by 39
Tau-imaging in neurodegeneration
Bischof, G. N., Endepols, H., van Eimeren, T., & Drzezga, A. E. (2017) · Methods · doi:10.1016/j.ymeth.2017.08.003 · Cited by 40
Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia
Lo, A., Evans, C. D., Mancini, M., Wang, H., Shcherbinin, S., Lu, M., Natanegara, F., & Willis, B. A. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210296 · Cited by 41
MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research
Zimmer, E. R., Parent, M. J., Cuello, A. C., Gauthier, S. G., & Rosa‐Neto, P. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.07.002 · Cited by 41
Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging
Shimojo, M., Higuchi, M., Suhara, T., & Sahara, N. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00482 · Cited by 37
A robust biomarker of large‐scale network failure in Alzheimer's disease
Wiepert, D. A., Lowe, V. J., Knopman, D. S., Boeve, B. F., Graff‐Radford, J., Petersen, R. C., Jack, C. R., & Jones, D. T. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.004 · Cited by 38
Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook
Vāvere, A. L., & Scott, P. J. H. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.05.001 · Cited by 39
Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy
Whitwell, J. L., Ahlskog, J. E., Tosakulwong, N., Senjem, M. L., Spychalla, A. J., Petersen, R. C., Jack, C. R., Lowe, V. J., & Josephs, K. A. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.12.016 · Cited by 40
Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias
Wren, M. C., Lashley, T., Årstad, E., & Sander, K. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0535-z · Cited by 43
Neuroimaging advances in Parkinson's disease
Rispoli, V., Schreglmann, S. R., & Bhatia, K. P. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000584 · Cited by 38
Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review
Ulanova, M., Poljak, A., Wen, W. X., Bongers, A., Gloag, L., Gooding, J. J., Tilley, R. D., Sachdev, P. S., & Braidy, N. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0316 · Cited by 39
PET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
[ 18 F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
Wolters, E. E., Papma, J. M., Verfaillie, S. C. J., Visser, D., Weltings, E., Groot, C., van der Ende, E. L., Giannini, L. A. A., Tuncel, H., Timmers, T., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012448 · Cited by 37
Patterns of tau pathology identified with 18 F‐MK‐6240 PET imaging
Kreisl, W. C., Lao, P. J., Johnson, A. S., Tomljanovic, Z., Klein, J., Polly, K., Maas, B., Laing, K. K., Chesebro, A. G., Igwe, K. C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12384 · Cited by 42
Tau Positron Emission Tomography ImagingPreprint
Kolb, H. C., & Andrés, J. I. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023721 · Cited by 37
Self-citation
Cryo-EM Structures of Chronic Traumatic Encephalopathy Tau Filaments with PET Ligand Flortaucipir
Shi, Y., Ghetti, B. F., Goedert, M., & Scheres, S. H. W. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168025 · Cited by 40
Imaging Protein Misfolding in the Brain Using β-Sheet Ligands
Harada, R., Okamura, N., Furumoto, S., & Yanai, K. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00585 · Cited by 41
The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease
Hsu, J., Lin, K., Hsiao, I., Huang, K., Liu, C., Wu, H.-C., Weng, Y., Huang, C., Chang, C., Yen, T., et al. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003164 · Cited by 35
Self-citation
Relationships Between Cognition and Neuropathological Tau in Alzheimer’s Disease Assessed by 18 F Flortaucipir PET
Devous, M. D., Fleisher, A., Pontecorvo, M. J., Lu, M., Siderowf, A. D., Navitsky, M. A., Kennedy, I. A., Southekal, S. S., Harris, T. S., & Mintun, M. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200808 · Cited by 38
In vivo evidence for pre‐symptomatic neuroinflammation in a MAPT mutation carrier
Bevan‐Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J. P., Aigbirhio, F. I., O'Brien, J. T., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.683 · Cited by 36
Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary
Rabinovici, G. D., Karlawish, J. H., Knopman, D. S., Snyder, H. M., Sperling, R. A., & Carrillo, M. C. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.03.002 · Cited by 35
Biological, Neuroimaging, and Neurophysiological Markers in Frontotemporal Dementia: Three Faces of the Same Coin
Borroni, B., Benussi, A., Premi, E., Alberici, A., Marcello, E. E., Gardoni, F., Luca, M. D., & Padovani, A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170584 · Cited by 41
Tau PET Imaging with [18F]PM-PBB3 in Frontotemporal Dementia with MAPT Mutation
Su, Y., Fu, J., Yu, J., Zhao, Q., Guan, Y., Zuo, C., Li, M., Tan, H., & Cheng, X. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200287 · Cited by 35
One-Stop Shop: 18 F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases
Hammes, J., Bischof, G. N., Bohn, K. P., Onur, O. A., Schneider, A., Fließbach, K., Hoenig, M. C., Jessen, F., Neumaier, B., Drzezga, A. E., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244061 · Cited by 37
cGMP production of the radiopharmaceutical [18F]MK ‐6240 for PET imaging of human neurofibrillary tangles
Collier, T. L., Yokell, D. L., Livni, E., Rice, P. A., Celen, S., Serdons, K., Neelamegam, R., Bormans, G. M., Harris, D., Walji, A. M., et al. (2017) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3496 · Cited by 36
Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease
Josephs, K. A., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Schwarz, C. G., Senjem, M. L., Machulda, M. M., Kantarci, K., Knopman, D. S., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado8076 · Cited by 40
In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice
Waldron, A., Wintmolders, C., Bottelbergs, A., Kelley, J. B., Schmidt, M. E., Stroobants, S. G., Langlois, X., & Staelens, S. G. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0158-6 · Cited by 34
Elevated 18 F-AV-1451 PET tracer uptake detected in incidental imaging findings
Lockhart, S. N., Ayakta, N., Winer, J. R., Joie, R. L., Rabinovici, G. D., & Jagust, W. J. (2017) · Neurology · doi:10.1212/wnl.0000000000003724 · Cited by 37
Discovery of N-(4-[18F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer
Rombouts, F. J. R., Declercq, L., Andrés, J.-I., Bottelbergs, A., Chen, L., Iturrino, L., Leenaerts, J. E., Mariën, J., Song, F., Wintmolders, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01759 · Cited by 35
Self-citation
Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients
Zhao, Q., Liu, M., Ha, L., Zhou, Y., & Initiative, A. D. N. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00486 · Cited by 39
[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation
Ali, F., Whitwell, J. L., Martin, P. R., Senjem, M. L., Knopman, D. S., Jack, C. R., Lowe, V. J., Petersen, R. C., Boeve, B. F., & Josephs, K. A. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8815-x · Cited by 38
Synthesis of a PET tau tracer [(11)C]PBB3 for imaging of Alzheimer's disease.
Wang, M., Gao, M., Xu, Z., & Zheng, Q.-H. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.08.053 · Cited by 32
Optimizing Central Nervous System Drug Development Using Molecular Imaging
Hargreaves, R. J., Hoppin, J., Sevigny, J., Patel, S., Chiao, P.-C., Klimas, M. T., & Verma, A. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.132 · Cited by 34
Contributions of imprecision in PET ‐ MRI rigid registration to imprecision in amyloid PET SUVR measurements
Schwarz, C. G., Jones, D. T., Gunter, J. L., Lowe, V. J., Vemuri, P., Senjem, M. L., Petersen, R. C., Knopman, D. S., Jack, C. R., & Initiative, T. A. D. N. (2017) · Human Brain Mapping · doi:10.1002/hbm.23622 · Cited by 34
Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases
Wilson, H., Politis, M., Rabiner, E. A., & Middleton, L. T. (2020) · Cells · doi:10.3390/cells9122581 · Cited by 34
The Role of Tau beyond Alzheimer’s Disease: A Narrative Review
Virgilio, E., Marchi, F. D., Contaldi, E., Dianzani, U., Cantello, R. M., Mazzini, L., & Comi, C. (2022) · Biomedicines · doi:10.3390/biomedicines10040760 · Cited by 32
18F-Flortaucipir in TDP-43 associated frontotemporal dementia
Smith, R., Santillo, A. F., Waldö, M. L., Strandberg, O., Berron, D., Vestberg, S., van Westen, D., van Swieten, J., Honer, M., & Hansson, O. (2019) · Scientific Reports · doi:10.1038/s41598-019-42625-9 · Cited by 33
Synthesis and preliminary evaluation of 2‐arylhydroxyquinoline derivatives for tau imaging
Tago, T., Furumoto, S., Okamura, N., Harada, R., Ishikawa, Y., Arai, H., Yanai, K., Iwata, R., & Kudo, Y. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3133 · Cited by 32
Tau Filaments and the Development of Positron Emission Tomography Tracers
Goedert, M., Yamaguchi, Y., Mishra, S. K., Higuchi, M., & Sahara, N. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00070 · Cited by 32
A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date
Lee, B. G., Leavitt, M. J., Bernick, C. B., Léger, G. C., Rabinovici, G. D., & Banks, S. J. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2017.5558 · Cited by 34
Disease-related patterns of in vivo pathology in Corticobasal syndrome
Initiative, A. D. N., Niccolini, F., Wilson, H., Hirschbichler, S. T., Yousaf, T., Pagano, G., Whittington, A., Caminiti, S. P., Erro, R., Holton, J. L., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4104-2 · Cited by 35
Test–retest repeatability of [ 18 F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
Timmers, T., Ossenkoppele, R., Visser, D., Tuncel, H., Wolters, E. E., Verfaillie, S. C. J., van der Flier, W. M., Boellaard, R., Golla, S. S. V., & van Berckel, B. N. M. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19879226 · Cited by 32
Fully automated synthesis of [18F]T807, a PET tau tracer for Alzheimer’s disease
Gao, M., Wang, M., & Zheng, Q. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.035 · Cited by 31
Highly Selective Tau-SPECT Imaging Probes for Detection of Neurofibrillary Tangles in Alzheimer’s Disease
Ono, M., Watanabe, H., Kitada, A., Matsumura, K., Ihara, M., & Saji, H. (2016) · Scientific Reports · doi:10.1038/srep34197 · Cited by 34
Neuroinflammation and β Amyloid Deposition in Alzheimer's Disease: In vivo Quantification with Molecular Imaging
Hommet, C., Mondon, K., Camus, V., Ribeiro, M. J., Beaufils, É., Arlicot, N., Corcia, P., Paccalin, M., Minier, F., Gosselin, T., et al. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000354363 · Cited by 36
Chronic traumatic encephalopathy: Contributions from the Boston University Center for the Study of Traumatic Encephalopathy
Riley, D., Robbins, C. A., Cantu, R. C., & Stern, R. A. (2015) · Brain Injury · doi:10.3109/02699052.2014.965215 · Cited by 32
Illuminating Protein Phase Separation: Reviewing Aggregation‐Induced Emission, Fluorescent Molecular Rotor and Solvatochromic Fluorophore Based Probes
Bai, Y., & Liu, Y. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202102344 · Cited by 30
Elevated medial temporal lobe and pervasive brain tau‐PET signal in normal participants
Lowe, V. J., Bruinsma, T. J., Min, H.-K. P., Lundt, E. S., Fang, P., Senjem, M. L., Boeve, B. F., Josephs, K. A., Pandey, M. K., Murray, M. E., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.005 · Cited by 32
A closer look at amyloid ligands, and what they tell us about protein aggregates
Chisholm, T. S., & Hunter, C. A. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00518f · Cited by 29
Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials
Harris, G. A., Hirschfeld, L. R., González, M. I., Pritchard, M. C., & May, P. C. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01775-x · Cited by 31
Imaging biomarkers in tauopathies
Dani, M., Edison, P., & Brooks, D. J. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.08.011 · Cited by 29
GANDALF: Generative Adversarial Networks with Discriminator-Adaptive Loss Fine-Tuning for Alzheimer’s Disease Diagnosis from MRI
Shin, H.-C., Ihsani, A., Xu, Z., Mandava, S., Sreenivas, S. T., Forster, C., Cha, J., & Initiative, A. D. N. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-59713-9_66 · Cited by 29
The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET
Mohammadi, Z., Alizadeh, H., Marton, J., & Cumming, P. D. (2023) · Biomolecules · doi:10.3390/biom13020290 · Cited by 28
Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
PET/CT of Dementia
Zukotynski, K., Kuo, P. H., Mikulis, D. J., Rosa‐Neto, P., Strafella, A. P., Subramaniam, R. M., & Black, S. E. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.18.19822 · Cited by 31
Synthesis and quality control of [18F]T807 for tau PET imaging
Holt, D. P., Ravert, H. T., & Dannals, R. F. (2016) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3425 · Cited by 28
Synthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, J., Burkett, B. J., Min, H.-K. P., Senjem, M. L., Dicks, E., Corriveau‐Lecavalier, N., Mester, C. T., Wiste, H. J., Lundt, E. S., Murray, M. E., et al. (2023) · Brain · doi:10.1093/brain/awad346 · Cited by 32
New Targets for the Development of PET Tracers for Imaging Neurodegeneration in Alzheimer Disease
Mach, R. H. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.127811 · Cited by 28
Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives as Potential Tau Imaging Agents
Zhou, K., Yang, F., Li, Y., Chen, Y., Zhang, X., Zhang, J., Wang, J., Dai, J., Cai, L., & Cui, M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01078 · Cited by 28
Concise and high-yield synthesis of T808 and T808P for radiosynthesis of [18F]-T808, a PET tau tracer for Alzheimer’s disease
Gao, M., Wang, M., & Zheng, Q. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.025 · Cited by 28
Central Nervous System Targeted Protein Degraders
Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023) · Biomolecules · doi:10.3390/biom13081164 · Cited by 30

Authors: Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., Mu, F., Sinha, A., Su, H., Szardenings, A. K., Walsh, J. C., Wang, E., Yu, C., Zhang, W., Zhao, T., & Kolb, H. C.
Affiliations: Siemens Healthcare (United States) (US)
Corresponding author: Kolb, Hartmuth C.
ORCID: Xia, Chun‐Fang
Liang, Qianwa
Liu, Changhui
Su, Helen
Szardenings, A. Katrin
Zhang, Wei
Kolb, Hartmuth C.
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2013-02-13
Volume: 9
Issue: 6
Pages: 666-676
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2012.11.008
OpenAlex: W1974444040
Cited by: 605
References: 41
Citations by year: 2026: 23 · 2025: 36 · 2024: 30 · 2023: 37 · 2022: 43 · 2021: 47 · 2020: 45 · 2019: 53 · 2018: 63 · 2017: 80 · 2016: 68 · 2015: 42 · 2014: 30 · 2013: 8
FWCI: 34.21
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alzheimer s & Dementia (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Animals, Autoradiography, Brain, Female, Fluorine Radioisotopes, Humans, Male, Mice, Transgenic, Middle Aged, Protein Binding, Tissue Distribution, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks